title: Lurasidone for schizophrenia.
abstract: Lurasidone (Latuda-Sunovion) is a new oral second-generation antipsychotic licensed for treating adults with schizophrenia. Although less likely to cause extrapyramidal adverse effects than first-generation antipsychotics, some second-generation antipsychotics cause weight gain that may increase the risk of diabetes, hypertension and raised lipid levels.1,2 Lurasidone is promoted as offering a balance between efficacy and tolerability, with reported negligible effects on weight and minimal effects on glucose and cholesterol.3 Here we review evidence for lurasidone's efficacy and safety, and consider how it compares with other antipsychotics.
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000069056:Lurasidone Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D015430:Weight Gain / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents; D000069056:Lurasidone Hydrochloride